Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aethlon Medical has filed a provisional patent with the US Patent and Trademark Office for the use of the Aethlon hemopurifier as a device that fills the unmet need of identifying circulating cancer biomarkers to assist in early detection of cancer, monitor cancer treatment and detect cancer recurrence.
Subscribe to our email newsletter
Researchers recently discovered that the Aethlon hemopurifier captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. Based on emerging data, Aethlon believes that the hemopurifier will evolve to become an adjunct treatment standard to enhance the benefit of therapies administered to cancer patients.
The hemopurifier addresses the previous challenge of isolating and identifying low-abundant cancer biomarkers from the complex mixture of substances contained in blood.
James Joyce, chairman and CEO of Aethlon Medical, said: “Beyond our opportunity to enter the cancer therapy market, we need to ensure our intellectual property estate also protects the use of the hemopurifier as an ultra sensitive method to diagnose the earliest stages of cancer.”